Sun Pharmaceutical Industries continues enjoying rich valuations on the bourses, thanks to its ability to consistently deliver good growth. The September quarter results were no different. The strong top line growth of 42 per cent came on the back of 16 per cent rise in domestic sales and 77 per cent jump in the US sales that together contributed four-fifths of sales.
2967
3590
4339
4999
999
1450
8083
0
240
312
2791
3377
4263
5158
339
495
574
580
4335
8670
2464
2981
99
125
249
499